<DOC>
	<DOC>NCT00125567</DOC>
	<brief_summary>The purpose of this study is to demonstrate in patients with Parkinson's disease that, when compared to levodopa/carbidopa, Stalevo will delay the time from initiation of study drug to the time an increase in antiparkinsonian medication is required due to inadequately controlled parkinsonian symptoms.</brief_summary>
	<brief_title>Stalevo in Early Wearing-Off Patients</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Entacapone</mesh_term>
	<criteria>Idiopathic Parkinson's disease Treatment with 3 equal daily doses of levodopa/carbidopa up to 450 mg/day Unchanged antiparkinsonian medication for 6 weeks prior to baseline Secondary or atypical parkinsonism Patients with daily unpredictable OFF periods or painful dyskinesia</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
</DOC>